HER2 status of breast carcinoma developed as a secondary malignancy after Hodgkin lymphoma treatment

Authors :: Zoran Tomasevic
Daniela Kolarevic
Zorka Milovanovic
Zorica Tomasevic
Source :: Journal of Clinical Oncology. 28:e21112-e21112
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: e21112 Background: HER2 overexpression is present in ∼20% of all breast carcinoma (BC) but it is not quite known whether this percentage is maintained in potentially radiotherapy induced BC. Radiot...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
medicine.medical_treatment
Secondary Malignancy
Radiation therapy
Internal medicine
medicine
Hodgkin lymphoma
skin and connective tissue diseases
Breast carcinoma
business

Full Text Access

Tools